Ogeda is engaged in the discovery and development of small molecule drugs that target G-protein coupled receptors (GPCRs). Under the deal, Astellas will pay around €500m for 100% equity
The trial will feature 80-120 patients having the severe form of the disease who will be randomized to receive treatment with either mepolizumab or placebo when added to the
The approval has been granted to treat patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test whose disease has progressed on or after an
The study’s primary objective was to test safety and tolerability of anabasum in adults with CF who had FEV1 ≥ 40% predicted and remained on background CF medications,
Ocrevus is a humanised monoclonal antibody that can selectively target CD20-positive B cells, a specific type of immune cell tha is expected to cause myelin (nerve cell insulation
The agency also granted priority review status with a Prescription Drug User Fee Act (PDUFA) set for third quarter of this year. Lynparza tablets are an investigational formulation and are
Zejula is a poly(ADP-ribose) polymerase (PARP) inhibitor which has to be taken orally daily once. It has been approved for the maintenance treatment of adult patients with recurrent epithelial
The studies have demonstrated that the sarecycline achieved the 12 week primary efficacy endpoints in the treatment of patients with moderate to severe acne. Sarecycline is a once-daily,
The trial results could not show the topical stearoyl Co-A desaturase-1, or SCD1 inhibitor, XEN801 producing any statistically considerable difference in the primary endpoint of the percent change
Pemphigus vulgaris is a severe life-threatening condition, which can be recognized by progressive painful blistering of the skin and mucous membranes. Rituxan is a type of antibody therapy,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.